Abstract:figure legend Food enters the gastrointestinal tract and causes release of the two incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide 1 (GLP‐1). Most GIP reaches the systemic circulation and thus stimulates insulin secretion from the pancreas, but most GLP‐1 is inactivated by the enzyme dipeptidyl peptidase‐4 (DPP‐4) before reaching the systemic circulation. Instead, GLP‐1 interacts with vagal sensory afferent and signals to the brain stem and the hypothalamus. By contrast, exogeneous GLP‐1 and GLP1 receptor agonists reach the circumventricular organs of the brain directly after injection and inhibit centres regulating appetite and reward. In 1964, it was proven that postprandial insulin secretion is largely regulated by gut hormones and, in 1973, it was proposed that a gut hormone would also regulate appetite and food intake. Several gut hormones were tested for metabolic actions with disappointing results until the discovery of the proglucagon derivative, glucagon‐like peptide‐1 (GLP‐1). This peptide from the distal intestine has preserved activity on insulin secretion in people with type 2 diabetes and turned out to regulate both secretion and motility in the gastrointestinal tract and importantly, appetite and food intake, thus functioning as an efficient 'ileal brake' hormone. However, the natural hormone acts predominantly via sensory afferent systems and is extremely rapidly removed from the circulation by enzymatic degradation and renal elimination, and increasing the doses merely results in nausea and vomiting. Lipidation of analogs turned out to provide both stability and limit renal elimination, and very slow up‐titration of dosing improves tolerance. Indeed, the most recent agonists may near‐normalize glycaemic control in type 2 diabetes, may cause weight losses of up to 25% of body weight, and significantly reduce cardiovascular risk, effects that resemble those of bariatric surgery. Thus, a solution to one of the most serious health problems of modern civilization, the increased morbidity and mortality of the metabolic syndrome, may be addressed by mobilization of one of the body's own regulatory mechanisms.

Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Are GLP-1R agonists the long-sought-after panacea for obesity?

GLP-1 and Amylin in the Treatment of Obesity

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

How GLP-1 went from being a hard-to-handle hormone to a blockbuster success

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

The central GLP-1: implications for food and drug reward

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities